Published in Nature on December 21, 1984
Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol (1985) 4.76
CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol (1987) 4.58
Comparison between viremia and antigenemia for detection of cytomegalovirus in blood. J Clin Microbiol (1988) 4.05
Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol (1989) 3.05
Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med (1989) 2.89
Sequence and structural organization of murine cytomegalovirus immediate-early gene 1. J Virol (1987) 2.84
Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol (1990) 2.78
Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses. J Exp Med (1988) 2.73
Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol (1992) 2.67
Characterization of the major immediate-early polypeptides encoded by murine cytomegalovirus. J Virol (1985) 2.41
A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol (1988) 2.34
Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products. J Virol (1987) 2.30
The 89,000-Mr murine cytomegalovirus immediate-early protein activates gene transcription. J Virol (1986) 2.08
Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol (1990) 1.99
Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol (1988) 1.97
Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol (1991) 1.96
Cloned long-term cytolytic T-lymphocyte line with specificity for an immediate-early membrane antigen of murine cytomegalovirus. J Virol (1986) 1.86
Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med (2003) 1.81
Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol (1994) 1.71
Human CD8+ herpes simplex virus-specific cytotoxic T-lymphocyte clones recognize diverse virion protein antigens. J Virol (1992) 1.71
CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol (2006) 1.70
Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype. J Virol (2002) 1.67
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med (1987) 1.58
Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinant vaccinia virus. J Exp Med (1987) 1.57
A nonstructural polypeptide encoded by immediate-early transcription unit 1 of murine cytomegalovirus is recognized by cytolytic T lymphocytes. J Exp Med (1987) 1.52
Late-phase expression of a murine cytomegalovirus immediate-early antigen recognized by cytolytic T lymphocytes. J Virol (1986) 1.48
Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol (1998) 1.47
Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes. J Virol (1987) 1.47
Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis. J Clin Invest (1992) 1.43
Herpes simplex virus type 1-specific cytotoxic T lymphocytes recognize virus nonstructural proteins. J Virol (1988) 1.37
Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting. J Virol (2005) 1.34
Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host. J Exp Med (1988) 1.34
DNA immunization confers protection against murine cytomegalovirus infection. J Virol (1996) 1.22
Processing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functions. J Virol (2002) 1.19
Molecular biology and immunology of cytomegalovirus. Biochem J (1987) 1.19
The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells. J Virol (2000) 1.18
Role of keratinocytes in human recurrent herpetic lesions. Ability to present herpes simplex virus antigen and act as targets for T lymphocyte cytotoxicity in vitro. J Clin Invest (1989) 1.11
Macrophages escape inhibition of major histocompatibility complex class I-dependent antigen presentation by cytomegalovirus. J Virol (2000) 1.10
MHC class I immune evasion in MCMV infection. Med Microbiol Immunol (2008) 1.10
Pseudorabies virus glycoprotein gIII is a major target antigen for murine and swine virus-specific cytotoxic T lymphocytes. J Virol (1990) 1.06
Investigation of the impact of the common animal facility contaminant murine norovirus on experimental murine cytomegalovirus infection. Virology (2009) 1.04
Animal cytomegaloviruses. Microbiol Rev (1990) 1.02
CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model. Med Microbiol Immunol (2008) 1.01
Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J Virol (2000) 1.00
Cytomegalovirus reactivation in critically ill immunocompetent hosts: a decade of progress and remaining challenges. Antiviral Res (2011) 1.00
A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction. J Virol (2004) 0.99
Association of a major transcriptional regulatory protein, ICP4, of herpes simplex virus type 1 with the plasma membrane of virus-infected cells. J Virol (1991) 0.92
Viral latency drives 'memory inflation': a unifying hypothesis linking two hallmarks of cytomegalovirus infection. Med Microbiol Immunol (2012) 0.91
Identification of different target glycoproteins for bovine herpes virus type 1-specific cytotoxic T lymphocytes depending on the method of in vitro stimulation. Immunology (1993) 0.90
Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum Immunol (2008) 0.86
The history of vaccination against cytomegalovirus. Med Microbiol Immunol (2015) 0.86
Murine cytomegalovirus immune evasion proteins operative in the MHC class I pathway of antigen processing and presentation: state of knowledge, revisions, and questions. Med Microbiol Immunol (2012) 0.86
A murine cytomegalovirus-neutralizing monoclonal antibody exhibits autoreactivity and induces tissue damage in vivo. Immunology (1994) 0.85
Prevention of autoimmune lysis by T cells with specificity for a heat shock protein by antisense oligonucleotide treatment. Proc Natl Acad Sci U S A (1994) 0.84
Reverse genetics modification of cytomegalovirus antigenicity and immunogenicity by CD8 T-cell epitope deletion and insertion. J Biomed Biotechnol (2010) 0.83
Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection. Med Microbiol Immunol (2012) 0.82
Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection. Clin Exp Immunol (1991) 0.78
M27 expressed by cytomegalovirus counteracts effective type I interferon induction of myeloid cells but not of plasmacytoid dendritic cells. J Virol (2014) 0.78
Mutual Interference between Cytomegalovirus and Reconstitution of Protective Immunity after Hematopoietic Cell Transplantation. Front Immunol (2016) 0.76
The cellular immune response to cell-associated and cell-free cytomegalovirus (CMV) antigens after primary CMV-infection in non-immunocompromised hosts: development and maintenance of CMV-latency and its influence on immunocompetence. Clin Exp Immunol (1988) 0.76
Protective CD8+ T-cell responses to cytomegalovirus driven by rAAV/GFP/IE1 loading of dendritic cells. J Transl Med (2008) 0.75
Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A (1997) 5.37
Cloning of the human cytomegalovirus (HCMV) genome as an infectious bacterial artificial chromosome in Escherichia coli: a new approach for construction of HCMV mutants. J Virol (1999) 4.84
Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs. J Virol (1985) 4.76
CD8-positive T lymphocytes specific for murine cytomegalovirus immediate-early antigens mediate protective immunity. J Virol (1987) 4.58
Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol (1999) 4.23
Cloning and mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial artificial chromosome. J Virol (2000) 4.09
Fast screening procedures for random transposon libraries of cloned herpesvirus genomes: mutational analysis of human cytomegalovirus envelope glycoprotein genes. J Virol (2000) 3.35
Molecular cloning and physical mapping of murine cytomegalovirus DNA. J Virol (1983) 3.11
Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell (1991) 2.99
Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes. J Exp Med (1989) 2.89
Sequence and structural organization of murine cytomegalovirus immediate-early gene 1. J Virol (1987) 2.84
A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes. Nature (1989) 2.76
Immune evasion by cytomegalovirus--survival strategies of a highly adapted opportunist. Trends Microbiol (1998) 2.75
Viral mechanisms of immune evasion. Immunol Today (2000) 2.74
A long and complex enhancer activates transcription of the gene coding for the highly abundant immediate early mRNA in murine cytomegalovirus. Proc Natl Acad Sci U S A (1985) 2.74
A ribonucleotide reductase homolog of cytomegalovirus and endothelial cell tropism. Science (2001) 2.70
Gamma interferon-dependent clearance of cytomegalovirus infection in salivary glands. J Virol (1992) 2.67
Temporal regulation of murine cytomegalovirus transcription and mapping of viral RNA synthesized at immediate early times after infection. J Virol (1984) 2.62
Rapid identification of essential and nonessential herpesvirus genes by direct transposon mutagenesis. Nat Biotechnol (1999) 2.61
Hierarchical and redundant lymphocyte subset control precludes cytomegalovirus replication during latent infection. J Exp Med (1998) 2.60
A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. Immunity (1997) 2.49
A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity (1997) 2.45
The cytolytic T lymphocyte response to the murine cytomegalovirus. II. Detection of virus replication stage-specific antigens by separate populations of in vivo active cytolytic T lymphocyte precursors. Eur J Immunol (1984) 2.44
Characterization of the major immediate-early polypeptides encoded by murine cytomegalovirus. J Virol (1985) 2.41
A nonstructural viral protein expressed by a recombinant vaccinia virus protects against lethal cytomegalovirus infection. J Virol (1988) 2.34
Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell (1989) 2.31
A role for the proteasome regulator PA28alpha in antigen presentation. Nature (1996) 2.30
Immediate-early genes of murine cytomegalovirus: location, transcripts, and translation products. J Virol (1987) 2.30
A cytomegalovirus glycoprotein re-routes MHC class I complexes to lysosomes for degradation. EMBO J (1999) 2.30
Cytomegalovirus prevents antigen presentation by blocking the transport of peptide-loaded major histocompatibility complex class I molecules into the medial-Golgi compartment. J Exp Med (1992) 2.29
The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med (1994) 2.26
Antibodies are not essential for the resolution of primary cytomegalovirus infection but limit dissemination of recurrent virus. J Exp Med (1994) 2.17
Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med (1994) 2.13
K3-mediated evasion of CD8(+) T cells aids amplification of a latent gamma-herpesvirus. Nat Immunol (2002) 2.13
The 89,000-Mr murine cytomegalovirus immediate-early protein activates gene transcription. J Virol (1986) 2.08
Structural organization, expression, and functional characterization of the murine cytomegalovirus immediate-early gene 3. J Virol (1992) 2.08
Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol (1993) 2.04
Cellular and molecular basis of the protective immune response to cytomegalovirus infection. Curr Top Microbiol Immunol (1990) 2.00
Efficacious control of cytomegalovirus infection after long-term depletion of CD8+ T lymphocytes. J Virol (1990) 1.99
A mouse cytomegalovirus glycoprotein, gp34, forms a complex with folded class I MHC molecules in the ER which is not retained but is transported to the cell surface. EMBO J (1997) 1.98
Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol (1988) 1.97
Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J Virol (1991) 1.96
Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor. J Gen Virol (1994) 1.89
The immunoevasive function encoded by the mouse cytomegalovirus gene m152 protects the virus against T cell control in vivo. J Exp Med (1999) 1.88
Cloned long-term cytolytic T-lymphocyte line with specificity for an immediate-early membrane antigen of murine cytomegalovirus. J Virol (1986) 1.86
Viral mechanisms of immune evasion. Trends Microbiol (2000) 1.85
Latency versus persistence or intermittent recurrences: evidence for a latent state of murine cytomegalovirus in the lungs. J Virol (1997) 1.82
Identification of the mouse cytomegalovirus genomic region affecting major histocompatibility complex class I molecule transport. J Virol (1995) 1.77
Coordinated dual cleavages induced by the proteasome regulator PA28 lead to dominant MHC ligands. Cell (1996) 1.76
Restoration of cytomegalovirus antigen presentation by gamma interferon combats viral escape. J Virol (1994) 1.71
Forward with BACs: new tools for herpesvirus genomics. Trends Genet (2000) 1.66
Presentation of CMV immediate-early antigen to cytolytic T lymphocytes is selectively prevented by viral genes expressed in the early phase. Cell (1989) 1.64
Focal transcriptional activity of murine cytomegalovirus during latency in the lungs. J Virol (1999) 1.59
Recognition of viral glycoproteins by influenza A-specific cross-reactive cytolytic T lymphocytes. J Exp Med (1980) 1.58
In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection. J Exp Med (1987) 1.58
Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinant vaccinia virus. J Exp Med (1987) 1.57
Enhancer requirement for murine cytomegalovirus growth and genetic complementation by the human cytomegalovirus enhancer. J Virol (1998) 1.56
A nonstructural polypeptide encoded by immediate-early transcription unit 1 of murine cytomegalovirus is recognized by cytolytic T lymphocytes. J Exp Med (1987) 1.52
The multiple immune-evasion genes of murine cytomegalovirus are not redundant: m4 and m152 inhibit antigen presentation in a complementary and cooperative fashion. J Exp Med (2001) 1.52
Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection. J Gen Virol (1993) 1.51
Late-phase expression of a murine cytomegalovirus immediate-early antigen recognized by cytolytic T lymphocytes. J Virol (1986) 1.48
Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol (1998) 1.47
Host immune response to cytomegalovirus: products of transfected viral immediate-early genes are recognized by cloned cytolytic T lymphocytes. J Virol (1987) 1.47
Identification of the murine cytomegalovirus glycoprotein B gene and its expression by recombinant vaccinia virus. J Virol (1992) 1.46
Alloreactive cytotoxic T lymphocytes generated in the presence of viral-derived peptides show exquisite peptide and MHC specificity. J Immunol (1993) 1.45
Characterization of the murine cytomegalovirus early transcription unit e1 that is induced by immediate-early proteins. J Virol (1990) 1.45
Reconstitution of CD8 T cells is essential for the prevention of multiple-organ cytomegalovirus histopathology after bone marrow transplantation. J Gen Virol (1998) 1.44
Virus attenuation after deletion of the cytomegalovirus Fc receptor gene is not due to antibody control. J Virol (1998) 1.44
Cytomegaloviral control of MHC class I function in the mouse. Immunol Rev (1999) 1.42
Simultaneous expression of CD4 and CD8 antigens by a substantial proportion of resting porcine T lymphocytes. Eur J Immunol (1987) 1.41
Interference with antigen processing by viruses. Curr Opin Immunol (1997) 1.40
Structure and expression of murine cytomegalovirus immediate-early gene 2. J Virol (1991) 1.37
Failure in generating hemopoietic stem cells is the primary cause of death from cytomegalovirus disease in the immunocompromised host. J Exp Med (1988) 1.34
Lack of MHC class I complex expression has no effect on spread and control of cytomegalovirus infection in vivo. J Gen Virol (1996) 1.33
A mouse model for cytomegalovirus infection. Curr Protoc Immunol (2001) 1.32
Patchwork pattern of transcriptional reactivation in the lungs indicates sequential checkpoints in the transition from murine cytomegalovirus latency to recurrence. J Virol (1999) 1.32
Monoclonal antibodies reactive with swine lymphocytes. I. Antibodies to membrane structures that define the cytolytic T lymphocyte subset in the swine. J Immunol (1984) 1.29
The luminal part of the murine cytomegalovirus glycoprotein gp40 catalyzes the retention of MHC class I molecules. EMBO J (2000) 1.28